Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $3.82, but opened at $3.58. Anbio Biotechnology shares last traded at $3.7760, with a volume of 391 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on Anbio Biotechnology
Anbio Biotechnology Price Performance
The stock’s fifty day simple moving average is $4.70 and its 200-day simple moving average is $15.98.
Institutional Investors Weigh In On Anbio Biotechnology
An institutional investor recently bought a new position in Anbio Biotechnology stock. State Street Corp acquired a new stake in Anbio Biotechnology (NASDAQ:NNNN – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,608 shares of the company’s stock, valued at approximately $161,000.
Anbio Biotechnology Company Profile
Anbio Biotechnology is a medical technology company focused on in vitro diagnostic products used to detect and monitor health conditions. Its offerings include diagnostic testing systems and related products designed for clinical and point-of-care settings. The company’s product portfolio includes testing equipment and diagnostic reagents, supporting the analysis of patient samples. These tools are intended to help healthcare providers obtain test results outside or alongside conventional laboratory workflows.
Further Reading
- Five stocks we like better than Anbio Biotechnology
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
